CA2513712A1 - Osteogenic composition - Google Patents

Osteogenic composition Download PDF

Info

Publication number
CA2513712A1
CA2513712A1 CA002513712A CA2513712A CA2513712A1 CA 2513712 A1 CA2513712 A1 CA 2513712A1 CA 002513712 A CA002513712 A CA 002513712A CA 2513712 A CA2513712 A CA 2513712A CA 2513712 A1 CA2513712 A1 CA 2513712A1
Authority
CA
Canada
Prior art keywords
rbmp
pyrrolidone
bmp
poly
lactide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002513712A
Other languages
English (en)
French (fr)
Inventor
Franz Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2513712A1 publication Critical patent/CA2513712A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002513712A 2003-01-30 2004-01-29 Osteogenic composition Abandoned CA2513712A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/354,856 2003-01-30
US10/354,856 US7074412B2 (en) 2003-01-30 2003-01-30 Pharmaceutical composition
PCT/IB2004/000577 WO2004067027A2 (en) 2003-01-30 2004-01-29 Osteogenic composition

Publications (1)

Publication Number Publication Date
CA2513712A1 true CA2513712A1 (en) 2004-08-12

Family

ID=32770436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002513712A Abandoned CA2513712A1 (en) 2003-01-30 2004-01-29 Osteogenic composition

Country Status (9)

Country Link
US (1) US7074412B2 (cg-RX-API-DMAC10.html)
EP (1) EP1589989A2 (cg-RX-API-DMAC10.html)
JP (1) JP2006519782A (cg-RX-API-DMAC10.html)
KR (1) KR20050105446A (cg-RX-API-DMAC10.html)
CN (1) CN100490893C (cg-RX-API-DMAC10.html)
AU (1) AU2004208569B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0407178A (cg-RX-API-DMAC10.html)
CA (1) CA2513712A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004067027A2 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7189409B2 (en) * 2004-03-09 2007-03-13 Inion Ltd. Bone grafting material, method and implant
US20060258578A1 (en) * 2005-05-10 2006-11-16 The University Of Zurich Pharmaceutical composition
KR100865759B1 (ko) * 2007-05-07 2008-10-29 울산대학교 산학협력단 사람의 골형성단백질-2를 암호화하는 유전자를 이용한 재조합된 사람의 골형성단백질-2의 제조방법
KR100932945B1 (ko) * 2009-01-16 2009-12-21 원광대학교산학협력단 골 분말과 피브린 글루로 이루어진 고형의 스캐폴드
KR100932948B1 (ko) * 2009-01-16 2009-12-21 원광대학교산학협력단 Ｂｍｐ-2를 함유하는 골 분말과 피브린 글루로 이루어진 고형의 스캐폴드
KR100932947B1 (ko) * 2009-01-16 2009-12-21 원광대학교산학협력단 안지오제닌을 함유하는 뼈 재생용 조성물
US8979534B2 (en) 2009-06-17 2015-03-17 The Trustees Of Columbia University In The City Of New York Tooth scaffolds
US20150335400A1 (en) * 2009-06-17 2015-11-26 The Trustees Of Columbia University In The City Of New York Tooth scaffolds
WO2012101173A1 (en) * 2011-01-26 2012-08-02 Universität Zürich N-methyl-2-pyrrolidone for prevention and treatment of bone loss
WO2017019833A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Compositions containing repair cells and cationic dyes
WO2017019832A1 (en) * 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions using repair cells and cationic dyes
US12383246B2 (en) 2020-10-12 2025-08-12 Abbott Cardiovascular Systems, Inc. Vessel closure device with improved safety and tract hemostasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
EP1161201A4 (en) * 1999-02-16 2006-07-19 Zimmer Orthobiologics Inc DEVICE AND METHOD FOR REGENERATING AND RESTORING CARTILAGE DEFECTS
US20030105530A1 (en) 2001-12-04 2003-06-05 Inion Ltd. Biodegradable implant and method for manufacturing one
US6926903B2 (en) * 2001-12-04 2005-08-09 Inion Ltd. Resorbable polymer composition, implant and method of making implant

Also Published As

Publication number Publication date
US7074412B2 (en) 2006-07-11
US20040152627A1 (en) 2004-08-05
WO2004067027A2 (en) 2004-08-12
CN100490893C (zh) 2009-05-27
CN1761481A (zh) 2006-04-19
AU2004208569A1 (en) 2004-08-12
BRPI0407178A (pt) 2006-02-07
AU2004208569B2 (en) 2008-07-31
EP1589989A2 (en) 2005-11-02
WO2004067027A3 (en) 2004-09-16
JP2006519782A (ja) 2006-08-31
KR20050105446A (ko) 2005-11-04
WO2004067027A9 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
US7074412B2 (en) Pharmaceutical composition
EP0535091B1 (en) Osteoinductive pharmaceutical formulations
Takahashi et al. Skull bone regeneration in nonhuman primates by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel
EP1220693B1 (en) Formulations for delivery of osteogenic proteins
Wildemann et al. Local and controlled release of growth factors (combination of IGF-I and TGF-beta I, and BMP-2 alone) from a polylactide coating of titanium implants does not lead to ectopic bone formation in sheep muscle
Kämmerer et al. Influence of a collagen membrane and recombinant platelet‐derived growth factor on vertical bone augmentation in implant‐fixed deproteinized bovine bone–animal pilot study
Tao et al. Single-dose local administration of parathyroid hormone (1–34, PTH) with β-tricalcium phosphate/collagen (β-TCP/COL) enhances bone defect healing in ovariectomized rats
WO2008103690A2 (en) Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw using pdgf and a bone matrix
US11596712B2 (en) Autologous bone graft substitute composition
Wei et al. Augmentation of fracture healing by hydroxyapatite/collagen paste and bone morphogenetic protein‐2 evaluated using a rat femur osteotomy model
AU2025204550A1 (en) Artificial periosteum
Harding et al. Manipulating the anabolic and catabolic response in bone graft remodeling: synergism by a combination of local BMP‐7 and a single systemic dosis of zoledronate
Özer et al. Locally administrated single-dose teriparatide affects critical-size rabbit calvarial defects: A histological, histomorphometric and micro-CT study
Sawada et al. A trial of alveolar cleft bone regeneration by controlled release of bone morphogenetic protein: an experimental study in rabbits
Gerova-Vatsova et al. Application of autogenous platelet-rich plasma in periodontology
Kim et al. Vertical Bone Augmentation Using Deproteinized Bovine Bone Mineral, Absorbable Collagen Sponge, and Recombinant Human Bone Morphogenetic Protein-2: An In Vivo Study in Rabbits.
Reynolds et al. Protein and peptide-based therapeutics in periodontal regeneration
Shi et al. Preventive effect of platelet-rich plasma/Bio-Oss granules composite on medication-related osteonecrosis of the jaw in a rat model
Honnami et al. Repair of rabbit segmental femoral defects by using a combination of tetrapod-shaped calcium phosphate granules and basic fibroblast growth factor-binding ion complex gel
Minagawa et al. Controlled Release of Granulocyte Colony‐Stimulating Factor Enhances Osteoconductive and Biodegradable Properties of Beta‐Tricalcium Phosphate in a Rat Calvarial Defect Model
EP1723961A2 (en) Pharmaceutical composition comprising at least one bone morphogenetic protein (BMP)
Casap et al. Imperforate titanium shell enclosing recombinant human bone morphogenetic protein-2–induced bone formation for high-profile dental implants in rabbit tibia
US8158685B2 (en) Method for bone growth
EP1475109A1 (en) Formulations for delivery of osteogenic proteins
WO2017203331A1 (en) Composition and methods for bone tissue engineering

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued